Gareth Sanger

Last updated

Gareth Sanger
Nationality United Kingdom
Employer
Website www.icms.qmul.ac.uk/neurogastro/staff/garethsanger.html

Dr Gareth J. Sanger (born 1953) is a British pharmacologist.

Sanger was a Research Fellow at King's College Hospital Medical School from 1977 to 1990. [1] He then spent a period in the pharmacological industry, [1] before being appointed, in 2009, Professor of Neuropharmacology, at Queen Mary University of London. [2]

Queen Mary University of London public research university in London, England; constituent college of the federal University of London

Queen Mary University of London (QMUL) is a public research university in London, England, and a constituent college of the federal University of London. It dates back to the foundation of London Hospital Medical College in 1785. Queen Mary College, named after Mary of Teck, was admitted to the University of London in 1915 and in 1989 merged with Westfield College to form Queen Mary and Westfield College. In 1995 Queen Mary and Westfield College merged with St Bartholomew's Hospital Medical College and the London Hospital Medical College to form the School of Medicine and Dentistry.

He has served as editor and reviews editor for the "British Journal of Pharmacology" and as an editorial board member for "Drug Discovery Today". [1]

<i>British Journal of Pharmacology</i> scientific journal

The British Journal of Pharmacology is a biweekly peer-reviewed medical journal covering all aspects of experimental pharmacology. It is published for the British Pharmacological Society by Wiley-Blackwell. It was established in 1946 as the British Journal of Pharmacology and Chemotherapy. The journal obtained its current title in 1968.

Drug Discovery Today is a monthly peer-reviewed scientific journal that is published by Elsevier. It was established in 1996 and publishes reviews on all aspects of preclinical drug discovery from target identification and validation through hit identification, lead identification and optimisation, to candidate selection.

Together with M Tyers he received the 1998 Pharmaceutical Research and Manufacturers of America (PhRMA) "Discoverer's Award" for their research into 5HT3 receptor/antiemesis, which led to the identification and development of the drug Kytril, [1] [2] an antiemetic to treat nausea and vomiting following chemotherapy.

An antiemetic is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer. They may be used for severe cases of gastroenteritis, especially if the patient is dehydrated.

Nausea medical symptom or condition

Nausea is an unpleasant, diffuse sensation of unease and discomfort, often perceived as an urge to vomit. While not painful, it can be a debilitating symptom if prolonged, and has been described as placing discomfort on the chest, upper abdomen, or back of the throat.

Chemotherapy treatment of cancer with one or more cytotoxic anti-neoplastic drugs

Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent, or it may aim to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

Related Research Articles

Roy Pounder was Professor of Medicine at the Royal Free and University College Medical School in London and clinical vice president of the Royal College of Physicians of London. He is now an Emeritus Professor of Medicine, of London University.

Professor Kenneth Dawson Bagshawe, FRS is a British oncologist, and Emeritus Professor of Medical Oncology, at Charing Cross Hospital.

Roderick John Flower, also known as Rod, is a British pharmacologist, and professor at Barts and The London School of Medicine and Dentistry. Dr. Flower is a member of the board of directors of Antibe Therapeutics and on the scientific advisory board of Morria.

Professor Miles Weatherall (1920-2007) was a British pharmacologist.

Leslie Lars Iversen, is a British pharmacologist, known for his work on the neurochemistry of synaptic transmitters.

Dr Frank Ralph Batchelor, known as Ralph, was a British biochemist and businessman.

Peter Doyle (chemist) industrial pharmaceutical chemist

Peter Doyle OBE (1921-2004) was a British chemist.

Professor Owen Lyndon Wade (1921-2008) was a British medical researcher and academic, described by the Royal College of Physicians as "one of the founding fathers of clinical pharmacology and therapeutics in the UK".

Professor Lawrence Peter Ormerod FRCP, FRCP(Edin), FRCP(Glas) is an English chest physician.

Professor Kenneth Reginald Harrap (1931-2017) was a British oncological biochemist.

Sir Marcus Henry Richmond,, known as Mark Richmond, is a British biochemist, microbiologist and academic.

Professor John Low Reid is a British clinical pharmacologist.

David J. Webb, is a British clinical pharmacologist.

Professor Hubert Frank Woods (1937-2016), known as Frank, was a British pharmacologist.

Dr Jeffrey Kenneth Aronson is a British clinical pharmacologist.

Sir Alasdair Muir Breckenridge, is a Scottish pharmacologist.

Professor D. Gareth R. Evans is a British medical geneticist.

Dr. Yeshwant S. Bakhle DPhil, DSc, is a British pharmacologist.

Tom Blackburn FBPharmacolS, FRSB is a British industrial pharmacologist.

Professor Richard Green is a British neuropharmacologist.

References

  1. 1 2 3 4 Daphne Christie; Tilli Tansey, eds. (2007), The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer, Wellcome Witnesses to Contemporary Medicine, History of Modern Biomedicine Research Group, ISBN   978-0-85484-112-7 ,  Wikidata Q29581749
  2. 1 2 "Gareth Sanger". The Conversation. Retrieved 26 June 2017.

The History of Modern Biomedicine Research Group (HoMBRG) is an academic organisation specialising in recording and publishing the oral history of twentieth and twenty-first century biomedicine. It was established in 1990 as the Wellcome Trust's History of Twentieth Century Medicine Group, and reconstituted in October 2010 as part of the School of History at Queen Mary University of London.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.